文献速递肿瘤 PET/CT骨显像与常规 SPECT

初诊未治疗前列腺癌患者PSMA PET/CT原发分期的可重复性取决于所用放射性示踪剂:一项回顾性研究

Reproducibility of PSMA PET/CT Imaging for Primary Staging of Treatment-Naïve Prostate Cancer Patients Depends on the Applied Radiotracer: A Retrospective Study.
PubMed 文献 · J Nucl Med · 2022-08-25

该回顾性研究在584例新诊断前列腺癌患者中比较了18F-DCFPyL、18F-PSMA-1007和68Ga-PSMA-11三种PSMA示踪剂PET/CT原发分期的观察者间变异。总体一致性在区域淋巴结、远处淋巴结、骨转移和内脏转移的Cohen κ分别为0.86、0.86、0.80和0.46。18F-PSMA-1007在骨转移、总体一致性和区域淋巴结方面观察者间变异显著高于其他示踪剂,作者建议对18F-PSMA-1007图像判读应谨慎并强烈建议进行培训。

要点

  • 584例新诊断前列腺癌患者中,18F-DCFPyL、18F-PSMA-1007和68Ga-PSMA-11分别用于205例(35.1%)、168例(28.8%)和211例(36.1%)。
  • 总体一致性:区域淋巴结κ=0.86,远处淋巴结κ=0.86,骨转移κ=0.80,内脏转移κ=0.46。
  • 18F-PSMA-1007在骨转移方面观察者间变异显著高于18F-DCFPyL(P=0.001)和68Ga-PSMA-11(P=0.03),在总体一致性和区域淋巴结方面显著高于18F-DCFPyL(P<0.001和P=0.01)。

核心结论

  • 三种临床常用PSMA示踪剂(18F-DCFPyL、18F-PSMA-1007和68Ga-PSMA-11)在新诊断前列腺癌患者中的观察者间变异存在差异。
  • 18F-PSMA-1007在骨转移方面的一致性显著较差,主要由于骨结构中的非特异性示踪剂摄取。
  • 作者认为,基于本研究结果,采用18F-PSMA-1007进行原发分期的PSMA PET/CT扫描应谨慎判读,并强烈建议针对该特定PSMA示踪剂的判读进行培训。

研究设计与样本

  • 回顾性纳入新诊断前列腺癌患者,所有PSMA PET/CT图像在高容量前列腺癌中心集中复阅,比较转诊医院的原始报告与复阅报告。
  • 采用Cohen κ分析评估观察者间变异,采用多变量逻辑回归分析研究三种PSMA示踪剂间观察者间变异的可能差异。
  • 共纳入584例新诊断前列腺癌患者,18F-DCFPyL、18F-PSMA-1007和68Ga-PSMA-11分别用于205例(35.1%)、168例(28.8%)和211例(36.1%)患者。

主要发现

  • 区域淋巴结转移、远处淋巴结转移、骨转移和内脏转移的总体一致性(Cohen κ分析)分别为0.86、0.86、0.80和0.46。
  • 18F-PSMA-1007在骨转移方面的观察者间变异显著高于18F-DCFPyL(P=0.001)和68Ga-PSMA-11(P=0.03)。
  • 18F-PSMA-1007在总体一致性和区域淋巴结转移方面的观察者间变异显著高于18F-DCFPyL(P<0.001和P=0.01)。

关键数值与推荐

  • 总体一致性(Cohen κ):区域淋巴结转移0.86,远处淋巴结转移0.86,骨转移0.80,内脏转移0.46。
  • 18F-PSMA-1007对比18F-DCFPyL:骨转移观察者间变异P=0.001,总体一致性P<0.001,区域淋巴结转移P=0.01。
  • 18F-PSMA-1007对比68Ga-PSMA-11:骨转移观察者间变异P=0.03。

临床怎么用

  • 作者认为,采用18F-PSMA-1007进行原发分期的PSMA PET/CT扫描应谨慎判读。
  • 作者强烈建议针对18F-PSMA-1007这一特定PSMA示踪剂的判读进行培训。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our purpose was to determine and compare the interobserver variability of 3 clinically frequently used radiotracers targeting the prostate-specific membrane antigen (PSMA), namely 18F-DCFPyL, 18F-PSMA-1007, and 68Ga-PSMA-11, in primary prostate cancer (PCa) staging. Methods: Patients with newly diagnosed PCa in whom PSMA PET/CT was performed for primary staging purposes were retrospectively included. All PSMA PET/CT images were centrally overread within a high-volume PCa center, and original reports (from referring hospitals) were compared with overread reports (from the overreading hospital). To assess the interobserver variability, a Cohen κ analysis was used. To study possible differences in interobserver variability between the 3 applied PSMA radiotracers, multivariate logistic regression analyses were used. Results: In total, 584 patients with newly diagnosed PCa were included in the analysis. 18F-DCFPyL, 18F-PSMA-1007, and 68Ga-PSMA-11 were used in 205 (35.1%), 168 (28.8%), and 211 (36.1%) patients, respectively. The overall agreement (Cohen κ analysis) for locoregional lymph node metastases, distant lymph node metastases, bone metastases, and visceral metastases was 0.86, 0.86, 0.80, and 0.46, respectively. 18F-PSMA-1007 showed a significantly increased interobserver variability regarding bone metastases, compared with 18F-DCFPyL and 68Ga-PSMA-11 (P = 0.001 and 0.03, respectively). Additionally, 18F-PSMA-1007 showed a significantly increased interobserver variability regarding overall agreement and locoregional lymph node metastases, compared with 18F-DCFPyL (P < 0.001 and P = 0.01, respectively). Conclusion: Interobserver variability differs among the 3 clinically frequently used PSMA radiotracers (18F-DCFPyL, 18F-PSMA-1007, and 68Ga-PSMA-11) in patients with newly diagnosed PCa. The agreement in bone metastases is significantly worse for 18F-PSMA-1007, mainly due to nonspecific tracer uptake in osseous structures. On the basis of our findings, PSMA PET/CT scans undertaken with 18F-PSMA-1007 in primary staging should be interpreted carefully, and training on interpreting this specific PSMA radiotracer is strongly advised.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Hagens MJ, Oprea-Lager DE, Vis AN, et al. Reproducibility of PSMA PET/CT Imaging for Primary Staging of Treatment-Naïve Prostate Cancer Patients Depends on the Applied Radiotracer: A Retrospective Study. J Nucl Med. 2022. PMID: 36008118. doi:10.2967/jnumed.121.263139

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。